Analyst Group

Analyst Group Comment on Genetic Analysis’ First Placement of the GA-map® Dysbiosis Test in Australia

Källa: MFN
Positiv

Sammanfattning

Genetic Analysis har lanserat sin GA-map® Dysbiosis Test i Australien via Centre for Digestive Diseases (CDD) i Sydney. Detta är en milstolpe för bolagets expansion och en validering av standardiserade diagnostik inom mikrobiommarknaden.

Analys

Den första placeringen i Australien öppnar en ny geografisk marknad för Genetic Analysis. Valet av ett ledande FMT-center stärker bolagets referensbas och förväntas stödja framtida internationella placeringar. Den finansiella påverkan förväntas dock ske gradvis snarare än omedelbart.

Insikter

  • • Öppnar en ny geografisk marknad i Australien.
  • • Stärker bolagets referensbas genom val av ledande FMT-center.
  • • Finansiell påverkan förväntas vara gradvis.

On August 21st, Genetic Analysis AS (”Genetic Analysis” or the ”Company”) announced the launch of the GA-map® Dysbiosis Test at the Centre for Digestive Diseases (CDD) in Sydney, Australia. The implementation marks the first placement of the Company’s microbiome testing technology in Australia. CDD is a specialist gastroenterology center recognized for its work within gastrointestinal disorders and fecal microbiota transplantation (FMT), and the test is intended to provide clinicians with a standardized tool for assessing gut microbiota composition in patients with conditions such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).

On August 21st, Genetic Analysis AS (”Genetic Analysis” or the ”Company”) announced the launch of the GA-map® Dysbiosis Test at the Centre for Digestive Diseases (CDD) in Sydney, Australia. The implementation marks the first placement of the Company’s microbiome testing technology in Australia. CDD is a specialist gastroenterology center recognized for its work within gastrointestinal disorders and fecal microbiota transplantation (FMT), and the test is intended to provide clinicians with a standardized tool for assessing gut microbiota composition in patients with conditions such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).

In summary, Analyst Group views the first Australian placement as a milestone in Genetic Analysis’ expansion strategy that opens a geographic market previously outside the Company’s footprint, and as a further validation of the shift toward standardized diagnostics in the microbiome market. That a clinically leading FMT center selects the GA-map® platform is assessed to strengthen the Company’s reference base and support subsequent placements internationally, though the financial impact is expected to accrue gradually rather than immediately.

Read Analyst Group’s comment here

About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.Read more about Analyst Group This is a press release from Analyst Group regarding the publication of a comment on Genetic Analysis. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.